

# Alexandra E Butler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154022/publications.pdf>

Version: 2024-02-01

118  
papers

8,711  
citations

117453

34  
h-index

43802

91  
g-index

122  
all docs

122  
docs citations

122  
times ranked

9440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis. <i>Diabetes Care</i> , 2022, 45, 267-272.	4.3	12
2	The role of exosomal miRNA in nonalcoholic fatty liver disease. <i>Journal of Cellular Physiology</i> , 2022, 237, 2078-2094.	2.0	25
3	Hypoglycemia Impairs the Heat Shock Protein Response: A Risk for Heat Shock in Cattle?. <i>Frontiers in Veterinary Science</i> , 2022, 9, 822310.	0.9	0
4	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. <i>Nature Communications</i> , 2022, 13, 946.	5.8	30
5	Diagnostic and Prognostic Protein Biomarkers of $\beta$ -Cell Function in Type 2 Diabetes and Their Modulation with Glucose Normalization. <i>Metabolites</i> , 2022, 12, 196.	1.3	5
6	Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis. <i>Nutrients</i> , 2022, 14, 1331.	1.7	11
7	The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3627-3637.	1.1	10
8	Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1483-1497.	2.2	1
9	Cardiovascular protection conferred by glucagon-like peptide-1 receptor agonists: A role for serum uric acid reduction?. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4237-4238.	1.1	0
10	Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases. <i>Life</i> , 2022, 12, 760.	1.1	4
11	The regulation of efferocytosis signaling pathways and adipose tissue homeostasis in physiological conditions and obesity: Current understanding and treatment options. <i>Obesity Reviews</i> , 2022, 23, .	3.1	6
12	Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. <i>Acta Diabetologica</i> , 2021, 58, 279-300.	1.2	10
13	Letter to the Editor: Do biomarkers of COVID-19 severity simply reflect a stress response in type 2 diabetes: Biomarker response to hypoglycemia. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154417.	1.5	2
14	Hypoglycaemia in type 2 diabetes exacerbates amyloid-related proteins associated with dementia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 338-349.	2.2	17
15	Chromogranin A-positive hormone-negative endocrine cells in pancreas in human pregnancy. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00223.	1.0	0
16	Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome. <i>Journal of Translational Medicine</i> , 2021, 19, 63.	1.8	2
17	Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?. <i>Frontiers in Endocrinology</i> , 2021, 12, 638621.	1.5	11
18	The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome. <i>Metabolism Open</i> , 2021, 9, 100079.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia. <i>Journal of Translational Medicine</i> , 2021, 19, 131.	1.8	6
20	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. <i>Scientific Reports</i> , 2021, 11, 6428.	1.6	13
21	apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001925.	1.2	7
22	Differing endometrial expression of calcium modulating transient receptor potential channels. <i>Journal of Translational Medicine</i> , 2021, 19, 113.	1.8	0
23	Mapping of type 2 diabetes proteins to COVID-19 biomarkers: A proteomic analysis. <i>Metabolism Open</i> , 2021, 9, 100074.	1.4	3
24	Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 651009.	1.5	7
25	Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome. <i>Scientific Reports</i> , 2021, 11, 5320.	1.6	16
26	Plasma heat shock protein response to euglycemia in type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002057.	1.2	12
27	Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002211.	1.2	4
28	Role of the DNAJ/HSP40 family in the pathogenesis of insulin resistance and type 2 diabetes. <i>Ageing Research Reviews</i> , 2021, 67, 101313.	5.0	12
29	The retinopathy-derived HbA1c threshold of 6.5% for type 2 diabetes also captures the risk of diabetic nephropathy in <sc>NHANES</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2109-2115.	2.2	8
30	Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity. <i>Frontiers in Endocrinology</i> , 2021, 12, 658304.	1.5	3
31	Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?. <i>Frontiers in Endocrinology</i> , 2021, 12, 665134.	1.5	2
32	Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index. <i>Journal of Translational Medicine</i> , 2021, 19, 239.	1.8	5
33	Vitamin D deficiency effects on cardiovascular parameters in women with polycystic ovary syndrome: A retrospective, cross-sectional study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 211, 105892.	1.2	4
34	Impact of severe hypoglycemia on the heat shock and related protein response. <i>Scientific Reports</i> , 2021, 11, 17057.	1.6	9
35	Association of microRNAs With Embryo Development and Fertilization in Women Undergoing Subfertility Treatments: A Pilot Study. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	4
36	Angiopietin-1: an early biomarker of diabetic nephropathy?. <i>Journal of Translational Medicine</i> , 2021, 19, 427.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Vitamin D association with the renin angiotensin system in polycystic ovary syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 214, 105965.	1.2	4
38	Relationship between total vitamin D metabolites and complications in patients with type 2 diabetes. <i>Biomedical Reports</i> , 2021, 14, 18.	0.9	4
39	Hypoglycemia-induced changes in complement pathways in type 2 diabetes. <i>Atherosclerosis Plus</i> , 2021, , .	0.3	2
40	Heat Shock-Related Protein Responses and Inflammatory Protein Changes Are Associated with Mild Prolonged Hypoglycemia. <i>Cells</i> , 2021, 10, 3109.	1.8	4
41	Potential Biomarkers to Predict Acute Ischemic Stroke in Type 2 Diabetes. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 744459.	1.6	5
42	The Impact of Incretin-Based Medications on Lipid Metabolism. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-10.	1.0	12
43	Association of vitamin D <sup>3</sup> and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092415.	1.1	18
44	Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?. <i>Metabolism Open</i> , 2020, 7, 100052.	1.4	20
45	Qatari Genotype May Contribute to Complications in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	1.0	1
46	Distinguishing between type 1 and type 2 diabetes. <i>BMJ, The</i> , 2020, 370, m2998.	3.0	15
47	Increased MicroRNA Levels in Women With Polycystic Ovarian Syndrome but Without Insulin Resistance: A Pilot Prospective Study. <i>Frontiers in Endocrinology</i> , 2020, 11, 571357.	1.5	14
48	Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications. <i>BMC Endocrine Disorders</i> , 2020, 20, 161.	0.9	17
49	Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154374.	1.5	6
50	Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations. <i>Scientific Reports</i> , 2020, 10, 18895.	1.6	9
51	Association of vitamin D2 and D3 with type 2 diabetes complications. <i>BMC Endocrine Disorders</i> , 2020, 20, 65.	0.9	22
52	Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. <i>Scientific Reports</i> , 2020, 10, 4750.	1.6	69
53	Long non-coding RNA expression in non-obese women with polycystic ovary syndrome and weight-matched controls. <i>Reproductive BioMedicine Online</i> , 2020, 41, 579-583.	1.1	2
54	Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection?. <i>Diabetes Care</i> , 2020, 43, e131-e133.	4.3	7

#	ARTICLE	IF	CITATIONS
55	microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. <i>Frontiers in Endocrinology</i> , 2020, 11, 206.	1.5	21
56	Association of Differing Qatari Genotypes with Vitamin D Metabolites. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-6.	0.6	4
57	COVID-19 biomarkers for severity mapped to polycystic ovary syndrome. <i>Journal of Translational Medicine</i> , 2020, 18, 490.	1.8	7
58	Relationship between total vitamin D metabolites and complications in patients with type 2 diabetes. <i>Biomedical Reports</i> , 2020, 14, 18.	0.9	11
59	Curcumin nanofibers for the purpose of wound healing. <i>Journal of Cellular Physiology</i> , 2019, 234, 5537-5554.	2.0	90
60	Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. <i>Drug Discovery Today</i> , 2019, 24, 256-262.	3.2	87
61	Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 223-230.	2.0	97
62	Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review. <i>Journal of Cellular Physiology</i> , 2019, 234, 1165-1178.	2.0	113
63	The protective role of curcumin in myocardial ischemia-reperfusion injury. <i>Journal of Cellular Physiology</i> , 2019, 234, 214-222.	2.0	125
64	Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 83.	1.7	88
65	Alterations in long noncoding RNAs in women with and without polycystic ovarian syndrome. <i>Clinical Endocrinology</i> , 2019, 91, 793-797.	1.2	15
66	Expression of microRNA in follicular fluid in women with and without PCOS. <i>Scientific Reports</i> , 2019, 9, 16306.	1.6	50
67	Characterization of Non-hormone Expressing Endocrine Cells in Fetal and Infant Human Pancreas. <i>Frontiers in Endocrinology</i> , 2019, 9, 791.	1.5	2
68	A response to ð response to ð Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. <i>Journal of Cellular Physiology</i> , 2019, 234, 9908-9909.	2.0	2
69	Expression and localization of transient receptor potential channels in the bovine uterus epithelium throughout the estrous cycle. <i>Molecular Biology Reports</i> , 2019, 46, 4077-4084.	1.0	1
70	IAPP toxicity activates HIF1 $\alpha$ /PFKFB3 signaling delaying $\beta$ -cell loss at the expense of $\beta$ -cell function. <i>Nature Communications</i> , 2019, 10, 2679.	5.8	55
71	Islet amyloidosis in a child with type 1 diabetes. <i>Islets</i> , 2019, 11, 44-49.	0.9	17
72	Pregnancy in human IAPP transgenic mice recapitulates beta cell stress in type 2 diabetes. <i>Diabetologia</i> , 2019, 62, 1000-1010.	2.9	9

#	ARTICLE	IF	CITATIONS
73	Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients. <i>Journal of Cellular Physiology</i> , 2019, 234, 2436-2446.	2.0	71
74	Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal. <i>Journal of Cellular Physiology</i> , 2019, 234, 1219-1229.	2.0	18
75	Curcumin as a therapeutic agent in leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 12404-12414.	2.0	45
76	Sodium-glucose cotransporter inhibitors and oxidative stress: An update. <i>Journal of Cellular Physiology</i> , 2019, 234, 3231-3237.	2.0	99
77	Impact of curcumin on toll-like receptors. <i>Journal of Cellular Physiology</i> , 2019, 234, 12471-12482.	2.0	48
78	Aerobic exercise can modulate the underlying mechanisms involved in the development of diabetic complications. <i>Journal of Cellular Physiology</i> , 2019, 234, 12508-12515.	2.0	23
79	Mechanisms of statin-induced new-onset diabetes. <i>Journal of Cellular Physiology</i> , 2019, 234, 12551-12561.	2.0	36
80	The therapeutic and diagnostic role of exosomes in cardiovascular diseases. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 313-323.	2.3	112
81	Therapeutic use of curcumin-encapsulated and curcumin-primed exosomes. <i>Journal of Cellular Physiology</i> , 2019, 234, 8182-8191.	2.0	81
82	Protective effects of plant-derived natural products on renal complications. <i>Journal of Cellular Physiology</i> , 2019, 234, 12161-12172.	2.0	28
83	Antidiabetic potential of saffron and its active constituents. <i>Journal of Cellular Physiology</i> , 2019, 234, 8610-8617.	2.0	41
84	Hormetic effects of curcumin: What is the evidence?. <i>Journal of Cellular Physiology</i> , 2019, 234, 10060-10071.	2.0	67
85	Genetics and rheumatoid arthritis susceptibility in Iran. <i>Journal of Cellular Physiology</i> , 2019, 234, 5578-5587.	2.0	10
86	Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial. <i>Phytotherapy Research</i> , 2018, 32, 1382-1387.	2.8	43
87	The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway. <i>Journal of Cellular Physiology</i> , 2018, 233, 6530-6537.	2.0	79
88	Curcumin in heart failure: A choice for complementary therapy?. <i>Pharmacological Research</i> , 2018, 131, 112-119.	3.1	40
89	Pathways governing development of stem cell-derived pancreatic $\beta^2$ cells: lessons from embryogenesis. <i>Biological Reviews</i> , 2018, 93, 364-389.	4.7	37
90	MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 967-981.	4.0	48

#	ARTICLE	IF	CITATIONS
91	The effect of statin therapy on endoplasmic reticulum stress. <i>Pharmacological Research</i> , 2018, 137, 150-158.	3.1	35
92	An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis. <i>Journal of the Endocrine Society</i> , 2018, 2, 1058-1066.	0.1	8
93	Therapeutic potential of curcumin in diabetic complications. <i>Pharmacological Research</i> , 2018, 136, 181-193.	3.1	155
94	The effect of fasting or calorie restriction on autophagy induction: A review of the literature. <i>Ageing Research Reviews</i> , 2018, 47, 183-197.	5.0	189
95	Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials. <i>Annals of Medicine</i> , 2018, 50, 485-493.	1.5	7
96	Monocyte-to-HDL cholesterol ratio as a prognostic marker in cardiovascular diseases. <i>Journal of Cellular Physiology</i> , 2018, 233, 9237-9246.	2.0	169
97	Increased Chromogranin A-Positive Hormone-Negative Cells in Chronic Pancreatitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2126-2135.	1.8	19
98	In the setting of $\beta$ -cell stress, the pancreatic duct gland transcriptome shows characteristics of an activated regenerative response. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G848-G854.	1.6	4
99	Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-3001.	1.8	18
100	Re-addressing the 2013 consensus guidelines for the diagnosis of insulinitis in human type 1 diabetes: is change necessary?. <i>Diabetologia</i> , 2017, 60, 753-755.	2.9	7
101	Cell cycle-related metabolism and mitochondrial dynamics in a replication-competent pancreatic beta-cell line. <i>Cell Cycle</i> , 2017, 16, 2086-2099.	1.3	27
102	Down Syndrome-Associated Diabetes Is Not Due To a Congenital Deficiency in $\beta$ Cells. <i>Journal of the Endocrine Society</i> , 2017, 1, 39-45.	0.1	7
103	Pancreatic Nonhormone Expressing Endocrine Cells in Children With Type 1 Diabetes. <i>Journal of the Endocrine Society</i> , 2017, 1, 385-395.	0.1	22
104	Neuropeptide Y expression marks partially differentiated $\beta$ cells in mice and humans. <i>JCI Insight</i> , 2017, 2, .	2.3	41
105	Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas. <i>Journal of Histotechnology</i> , 2016, 39, 59-65.	0.2	26
106	Increased Frequency of Hormone Negative and Polyhormonal Endocrine Cells in Lean Individuals With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3628-3636.	1.8	51
107	Increased Hormone-Negative Endocrine Cells in the Pancreas in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3487-3496.	1.8	50
108	Evaluation of immunohistochemical staining for glucagon in human pancreatic tissue. <i>Journal of Histotechnology</i> , 2016, 39, 8-16.	0.2	3

#	ARTICLE	IF	CITATIONS
109	Î²-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of Î²-Cell Dedifferentiation and Degranulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 523-532.	1.8	107
110	Î²-Cell Identity in Type 2 Diabetes: Lost or Found?: Figure 1. <i>Diabetes</i> , 2015, 64, 2698-2700.	0.3	9
111	Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. <i>Diabetes</i> , 2013, 62, 2595-2604.	0.3	381
112	Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. <i>Diabetes</i> 2013;62:2595-2604. <i>Diabetes</i> , 2013, 62, e19-e22.	0.3	11
113	Î²-Cell Dysfunctional ERAD/Ubiquitin/Proteasome System in Type 2 Diabetes Mediated by Islet Amyloid Polypeptideâ€œInduced UCH-L1 Deficiency. <i>Diabetes</i> , 2011, 60, 227-238.	0.3	103
114	Î²-Cell Replication Is the Primary Mechanism Subservicing the Postnatal Expansion of Î²-Cell Mass in Humans. <i>Diabetes</i> , 2008, 57, 1584-1594.	0.3	616
115	Relationship Between Î²-Cell Mass and Fasting Blood Glucose Concentration in Humans. <i>Diabetes Care</i> , 2006, 29, 717-718.	4.3	184
116	Diabetes Due to a Progressive Defect in Î²-Cell Mass in Rats Transgenic for Human Islet Amyloid Polypeptide (HIP Rat): A New Model for Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, 1509-1516.	0.3	239
117	Î²-Cell Deficit and Increased Î²-Cell Apoptosis in Humans With Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 102-110.	0.3	3,615
118	Increased Î²-Cell Apoptosis Prevents Adaptive Increase in Î²-Cell Mass in Mouse Model of Type 2 Diabetes: Evidence for Role of Islet Amyloid Formation Rather Than Direct Action of Amyloid. <i>Diabetes</i> , 2003, 52, 2304-2314.	0.3	374